Varsha Gandhi, PhD, on Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Varsha Gandhi, PhD, on Ibrutinib

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL

CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL

Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy

Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL

Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL